financetom
Business
financetom
/
Business
/
Flowers Foods Q3 net sales up 3%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Flowers Foods Q3 net sales up 3%
Nov 6, 2025 2:16 PM

Overview

* Flowers Foods ( FLO ) Q3 net sales rise 3% to $1.227 bln, meeting analyst expectations

* Adjusted EPS for Q3 meets analyst expectations at $0.23

* Net income for Q3 falls 39.2% due to higher interest expenses

Outlook

* Company forecasts 2025 adjusted EBITDA of $515 mln to $532 mln

* Flowers Foods ( FLO ) anticipates 2025 adjusted EPS of $1.02 to $1.08

Result Drivers

* SIMPLE MILLS ACQUISITION - Contributed $70.7 mln to net sales, offsetting pricing/mix and volume declines

* CHALLENGING ENVIRONMENT - Higher interest expense and consumer challenges led to a 39.2% decrease in net income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Meet $1.23 $1.23

bln bln (8

Analysts

)

Q3 Meet $0.23 $0.23 (6

Adjusted Analysts

EPS )

Q3 EPS $0.19

Q3 $48.70

Adjusted mln

Net

Income

Q3 Net $39.50

Income mln

Q3 $118.10

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the food processing peer group is "buy."

* Wall Street's median 12-month price target for Flowers Foods Inc ( FLO ) is $15.00, about 19.3% above its November 5 closing price of $12.10

* The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia
Rezolute Says it Gets Breakthrough Therapy Designation From US FDA for Ersodetug to Treat Hypoglycemia
Jan 7, 2025
10:34 AM EST, 01/07/2025 (MT Newswires) -- Rezolute ( RZLT ) said Tuesday it has received the US Food and Drug Administration's Breakthrough Therapy designation for its ersodetug monoclonal antibody to treat hypoglycemia due to congenital hyperinsulinism. The regulator's decision was based on the company's phase 2b trial of ersodetug in patients with congenital hyperinsulinism, which safely showed significant improvements...
Update: JPMorgan to Leave Net-Zero Banking Alliance
Update: JPMorgan to Leave Net-Zero Banking Alliance
Jan 7, 2025
10:35 AM EST, 01/07/2025 (MT Newswires) -- (Updates throughout with JPMorgan's ( JPM ) comments.) JPMorgan ( JPM ) is leaving climate group Net-Zero Banking Alliance, a company spokesperson told MT Newswires Tuesday. We will continue to work independently to advance the interests of our firm, our shareholders and our clients and remain focused on pragmatic solutions to help further...
NEO Battery Materials Launches New Product Line With
NEO Battery Materials Launches New Product Line With "Breakthrough" Battery Capacity
Jan 7, 2025
10:30 AM EST, 01/07/2025 (MT Newswires) -- NEO Battery Materials ( NBMFF ) on Tuesday announced the launch of an advanced high-performance silicon anode product with breakthrough battery capacity. The NBMSiDE P-300 product line showed a 43% to 130% improvement in initial battery capacity over traditional graphite anodes with less material used, the company said. NEO, which has submitted a...
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Actuate Therapeutics Gets Orphan Medicinal Product Label for Elraglusib in EU
Jan 7, 2025
10:34 AM EST, 01/07/2025 (MT Newswires) -- Actuate Therapeutics ( ACTU ) said Tuesday that the European Medicines Agency has granted orphan medicinal product designation to elraglusib for the treatment of pancreatic ductal adenocarcinoma. The company said the designation is granted to therapies intended for the treatment of life-threatening diseases that affect no more than two in 10,000 people in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved